Multiple Myeloma (MM) Completed Phase 2 Trials for Lenalidomide (DB00480)

Also known as: MULTIPLE MYELOMA (MM) / Multiple myeloma / Myeloma, Multiple / Multiple Myelomas / Multiple Myeloma(MM) / Plasma cell myelomas / Myelomatosis multiple / Peripheral plasma cell myeloma / Myelomatosis / Multiple myeloma myelomatosis / Plasma cell myeloma / Myeloma / Multiple myeloma with failed remission

DBCOND0040908 (Multiple Myeloma (MM))Completed2 IdentifierTitlePurposeDrugs
NCT00807599Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance LTreatment
NCT02159365Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsTreatment
NCT02206503Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)Treatment
NCT02331368Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple MyelomaTreatment
NCT01215344First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With VelcadeTreatment
NCT01651039Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)Treatment
NCT01782963Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)Treatment
NCT01270932Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure PatientsTreatment
NCT01206205Frontline Therapy in de Novo Multiple Myeloma Patients Under 65Treatment
NCT00051116A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple MyelomaTreatment
NCT00065351Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple MyelomaTreatment
NCT00091260CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic AmyloidosisTreatment
NCT00378209Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple MyelomaTreatment
NCT00540644Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple MyelomaTreatment
NCT00581919Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple MyelomaTreatment
NCT00617591Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)Treatment
NCT00679367Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisTreatment
NCT00691704Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance TherapyTreatment
NCT00779922Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
NCT00847639Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple MyelomaTreatment
NCT00908232Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VDTreatment
NCT00961467RMPT for Relapsed/Refractory Multiple MyelomaTreatment
NCT01160484Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple MyelomaTreatment
NCT01237249Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose DexamethasoneTreatment
NCT01242930Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple MyelomaTreatment
NCT01349569Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete RemissionTreatment
NCT01450215Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple MyelomaTreatment
NCT01593410Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaTreatment
NCT01701076Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple MyelomaTreatment
NCT02348528Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearTreatment
NCT02471820Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma PatientsTreatment